Cynata Therapeutics Limited (ASX:CYP)

Market Cap	3.41M -93.8%
Revenue (ttm)	1.71M -9.2%
Net Income	-9.25M
EPS	-0.04
Shares Out	243.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,691,256
Open	0.0130
Previous Close	0.0120
Day's Range	0.0130 - 0.0160
52-Week Range	0.0100 - 0.4350
Beta	1.12
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYP

Financial Performance

In fiscal year 2026, Cynata Therapeutics's revenue was 1.71 million, a decrease of -9.20% compared to the previous year's 1.89 million. Losses were -9.25 million, -1.51% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error